Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)

Labbe Catherine; Cabanero Michael; Korpanty Grzegorz J.; Tomasini Pascale; Doherty Mark K.; Mascaux Celine; Jao Kevin; Pitcher Bethany; Wang Rick; Pintilie Melania; Leighl Natasha B.; Feld Ronald; Liu Geoffrey; Bradbury Penelope Ann; Kamel-Reid Suzanne; Tsao Ming-Sound; Shepherd Frances A.

首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)

【24h】

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)

机译：TP53共突患者EGFR-突变非小细胞肺癌（NSCLC）患者的预后及预测作用

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction TP53 mutations are common in non-small cell lung cancer (NSCLC) and have been reported as prognostic of poor outcome. The impact of TP53 co-mutations in epidermal growth factor receptor (EGFR)-mutated NSCLC is unclear.

机译：引言TP53突变在非小细胞肺癌（NSCLC）中是常见的，并且已被报告为差的结果预后。表皮生长因子受体（EGFR） - 矫正NSCLC中TP53共突变的影响尚不清楚。

著录项

来源
《Lung cancer: Journal of the International Association for the Study of Lung Cancer》 |2017年第2017期|共7页
作者
Labbe Catherine; Cabanero Michael; Korpanty Grzegorz J.; Tomasini Pascale; Doherty Mark K.; Mascaux Celine; Jao Kevin; Pitcher Bethany; Wang Rick; Pintilie Melania; Leighl Natasha B.; Feld Ronald; Liu Geoffrey; Bradbury Penelope Ann; Kamel-Reid Suzanne; Tsao Ming-Sound; Shepherd Frances A.;
展开▼
作者单位

Univ Hlth Network Princess Margaret Canc Ctr Div Med Oncol &

Hematol 610 Univ Ave Toronto ON;

Univ Hlth Network Princess Margaret Canc Ctr Div Med Oncol &

Hematol 610 Univ Ave Toronto ON;

Queens Univ Canadian Canc Trials Grp 10 Stuard St Kingston ON K7L 3N6 Canada;

Aix Marseille Univ Marseille Hosp Publ Assistance 80 Rue Brochier F-13005 Marseille France;

Univ Hlth Network Princess Margaret Canc Ctr Div Med Oncol &

Hematol 610 Univ Ave Toronto ON;

Aix Marseille Univ Marseille Hosp Publ Assistance 80 Rue Brochier F-13005 Marseille France;

Hop Sacre Coeur Montreal Div Med Oncol &

Hematol 5400 Blvd Gouin Ouest Montreal PQ H4J 1C5;

Univ Hlth Network Princess Margaret Canc Ctr Div Med Oncol &

Hematol 610 Univ Ave Toronto ON;

Univ Hlth Network Princess Margaret Canc Ctr Div Med Oncol &

Hematol 610 Univ Ave Toronto ON;

Univ Hlth Network Princess Margaret Canc Ctr Div Med Oncol &

Hematol 610 Univ Ave Toronto ON;

Univ Hlth Network Princess Margaret Canc Ctr Div Med Oncol &

Hematol 610 Univ Ave Toronto ON;

Univ Hlth Network Princess Margaret Canc Ctr Div Med Oncol &

Hematol 610 Univ Ave Toronto ON;

Univ Hlth Network Princess Margaret Canc Ctr Div Med Oncol &

Hematol 610 Univ Ave Toronto ON;

Univ Hlth Network Princess Margaret Canc Ctr Div Med Oncol &

Hematol 610 Univ Ave Toronto ON;

Univ Hlth Network Dept Pathol 200 Elizabeth St Toronto ON M5G 2C4 Canada;

Univ Hlth Network Dept Pathol 200 Elizabeth St Toronto ON M5G 2C4 Canada;

Univ Hlth Network Princess Margaret Canc Ctr Div Med Oncol &

Hematol 610 Univ Ave Toronto ON;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
TP53; EGFR; Non-small cell lung cancer; Survival; Tyrosine kinase inhibitors;

机译：TP53;EGFR;非小细胞肺癌;存活;酪氨酸激酶抑制剂;

相似文献

外文文献
中文文献
专利

1. 中国乳腺癌患者循环肿瘤DNA中TP53突变的临床特征及预后价值 [J] . 易宗毕, 马飞, 荣国华, 癌症（英文版） . 2021,第005期
2. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC) [J] . Labbe Catherine, Cabanero Michael, Korpanty Grzegorz J., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2017,第期

机译：TP53共突患者EGFR-突变非小细胞肺癌（NSCLC）患者的预后及预测作用
3. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)Sabine Schmid, Oliver Gautschi, Sacha Rothschild, ^z>Michael Mark, Patrizia Froesch, Dirk Klingbiel, Hermann Reichegger, Wolfram Jochum, Joachim Diebold, Martin Fruh, [J] . Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第4期

机译：ALK阳性非小细胞肺癌（NSCLC）患者的临床结果（NSCLC）患者DE Novo EGFR或KRAS共突变接受酪氨酸激酶抑制剂（TKIS）Sabine Schmid，Oliver Gautschi，Saha Rothschild，^ Z> Michael Mark，Patrizia Frosech， Dirk Klingbiel，Hermann Reichegger，Wolfram Jochum，Joachim Diebold，Martin Fruh，
4. PUB100 Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI) [J] . Sabine Schmid, Oliver Gautschi, Sacha Rothschild, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：PUB100非小细胞肺癌（NSCLC）临床结果（NSCLC）患者ALK共突（EGFR或KRA）接受酪氨酸激酶抑制剂（TKI）
5. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
6. Predictors of changes in health-related quality of life during chemotherapy in an advanced non-small cell lung cancer patient population [D] . Shallwani, Shirin Mehdi 2010

机译：非小细胞肺癌晚期患者化疗期间健康相关生活质量变化的预测因子
7. Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11 KRAS and TP53 mutations and co-mutations on outcome [O] . Alberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti, 2021

机译：下一代测序液体活检在免疫检查点抑制剂治疗的先进非小细胞肺癌患者中的作用：STK11KRAS和TP53突变的影响和共生突变
8. Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations [O] . Paolo Bironzo, Maria Lucia Reale, Tessa Sperone, 2021

机译：表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）患者对酪氨酸激酶抑制剂（TKIS）的临床特征：共突变的预测和预测作用

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)

摘要

著录项

相似文献

相关主题

期刊订阅